T
TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
最近更新时间: 6小时之前14.95
-0.26 (-1.71%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Trevi Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
0.0
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.75% |
| 机构持股比例 | 79.20% |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HEFFERNAN MICHAEL THOMAS | - | 15.04 | -39,473 | -593,674 |
| 累积净数量 | -39,473 | |||
| 累积净值 ($) | -593,674 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 15.04 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HEFFERNAN MICHAEL THOMAS | 董事 | 15 Sep 2026 | 自动卖出 (-) | 39,473 | 15.04 | 593,674 |
| HEFFERNAN MICHAEL THOMAS | 董事 | 15 Sep 2026 | 执行期权 | 39,473 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合